{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:37:09Z","timestamp":1788907029726,"version":"build-2803163510"},"reference-count":24,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cannabis &amp; Cannabinoid Research"],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Benzodiazepines are a class of medication with sedative properties, commonly used for anxiety and other neurological conditions. These medications are associated with several well-known adverse effects. This observational study aims to investigate the reduction of benzodiazepine use in patients using prescribed medical cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was performed on a cohort of 146 medical cannabis patients (average age 47 years, 61% female, 54% reporting prior use of cannabis) who reported benzodiazepine use at initiation of cannabis therapy. These data are a part of a database gathered by a medical cannabis clinic (Canabo Medical). Descriptive statistics were used to quantify associations of the proportion of benzodiazepine use with time on medical cannabis therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>After completing an average 2-month prescription course of medical cannabis, 30.1% of patients had discontinued benzodiazepines. At a follow-up after two prescriptions, 65 total patients (44.5%) had discontinued benzodiazepines. At the final follow-up period after three medical cannabis prescription courses, 66 total patients (45.2%) had discontinued benzodiazepine use, showing a stable cessation rate over an average of 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Within a cohort of 146 patients initiated on medical cannabis therapy, 45.2% patients successfully discontinued their pre-existing benzodiazepine therapy. This observation merits further investigation into the risks and benefits of the therapeutic use of medical cannabis and its role relating to benzodiazepine use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/can.2018.0020","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T10:42:30Z","timestamp":1548326550000},"page":"214-218","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":44,"title":["Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis"],"prefix":"10.1177","volume":"4","author":[{"given":"Chad","family":"Purcell","sequence":"first","affiliation":[{"name":"Dalhousie Medical School Class of 2019, Dalhousie University Faculty of Medicine, Undergraduate Medical Education, Halifax, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Economics, Acadia University, Wolfville, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Moolman","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2014Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Mark","family":"Taylor","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology\u2014Head and Neck Surgery, Department of Surgery, Dalhousie University, Halifax, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,9,23]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"CPS [Internet]. Ottawa (ON): Canadian Pharmacists Association; c2016 [updated May 2015; cited April 2017]. Benzodiazepines [CPhA monograph]. Available at: http:\/\/www.e-cps.ca or http:\/\/www.myrxtx.ca Accessed January15 2019. Also available in paper copy from the publisher. Benzodiazepines. 2015."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03563.x"},{"key":"e_1_3_3_4_2","volume-title":"Basic & Clinical Pharmacology","author":"Trevor AJ","year":"2015","unstructured":"Trevor AJ. Sedative-hypnotic drugs. In: Katzung BG, , Trevor AJ, eds. Basic & Clinical Pharmacology, 13e. New York, NY: McGraw-Hill Medical, 2015.","edition":"13"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0019-8"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.1763"},{"key":"e_1_3_3_7_2","unstructured":"Health Canada. Canadian alcohol and drug use monitoring survey: Summary of results for 2012. 2014. Available at: http:\/\/www.hc-sc.gc.ca\/hc-ps\/drugs-drogues\/stat\/_2012\/summary-sommaire-eng.php Accessed January15 2019."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0004867415616695"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1694"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0012"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2017.01.011"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2013.08.010"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-7-4"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117699616"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-018-0862-2"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.209"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90003-X"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.01.004"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1048"},{"key":"e_1_3_3_20_2","first-page":"1","article-title":"Effects of marijuana on mental health: anxiety disorders","author":"Stoner SA","year":"2017","unstructured":"Stoner SA. Effects of marijuana on mental health: anxiety disorders. Alcohol Drug Abus Inst. 2017;(June):1\u20136.","journal-title":"Alcohol Drug Abus Inst"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-015-0387-1"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.2174\/1871527313666140612114838"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-010-2036-z"},{"key":"e_1_3_3_24_2","unstructured":"Health Canada. Cannabis in Canada: Cannabis Licensed Producers Market Data. 2018. Available at: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-medication\/cannabis\/licensed-producers\/market-data.html Accessed January15 2019."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2014.02.009"}],"container-title":["Cannabis &amp; Cannabinoid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/can.2018.0020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2018.0020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/can.2018.0020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:10:50Z","timestamp":1777385450000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/can.2018.0020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,1]]}},"alternative-id":["10.1089\/can.2018.0020"],"URL":"https:\/\/doi.org\/10.1089\/can.2018.0020","relation":{},"ISSN":["2578-5125","2378-8763"],"issn-type":[{"value":"2578-5125","type":"print"},{"value":"2378-8763","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}